<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03303092</url>
  </required_header>
  <id_info>
    <org_study_id>406-102-00002</org_study_id>
    <secondary_id>JapicCTI-173725</secondary_id>
    <nct_id>NCT03303092</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of subcutaneous (SC) administration of TEV-48125 (monthly
      TEV-48125 225 mg and TEV-48125 675 mg once over a period of 3 months) compared with placebo
      for preventive treatment in Episodic Migraine patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2017</start_date>
  <completion_date type="Actual">November 22, 2019</completion_date>
  <primary_completion_date type="Actual">November 22, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in the monthly (28 days) average number of migraine days during the 12-week period after the first dose of Investigational Medicinal Product (IMP)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects reaching at least 50% reduction in the monthly average number of migraine days during the 12-week period after the first dose of IMP</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the monthly average number of days with use of any acute headache medications during the 12-week period after the first dose of IMP</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the monthly average number of migraine days during the 12-week period after the first dose of IMP in patients not receiving concomitant preventive migraine medications</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in disability score, as measured by the MIDAS questionnaire, at 4 weeks after the final (third) dose of IMP</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">453</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>TEV-48125 (225/225/225 mg) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TEV-48125 will be subcutaneously administered once monthly for 3 months (225/225/225 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TEV-48125 (675 mg/placebo/placebo) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months (675 mg/placebo/placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be subcutaneously administered once monthly for 3 months (placebo/placebo/placebo).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEV-48125</intervention_name>
    <description>TEV-48125 will be subcutaneously administered once monthly for 3 months.</description>
    <arm_group_label>TEV-48125 (225/225/225 mg) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEV-48125 or placebo</intervention_name>
    <description>TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.</description>
    <arm_group_label>TEV-48125 (675 mg/placebo/placebo) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be subcutaneously administered once monthly for 3 months.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has a history of migraine (according to The International Classification of
             Headache Disorders, third edition [beta version] criteria) or clinical judgment
             suggests a migraine diagnosis

          -  Patient fulfills the criteria for Episodic migraine in baseline information collected
             during the 28 day screening period

          -  Not using preventive migraine medications for migraine or other medical conditions or
             using no more than 1 preventive migraine medication for migraine or other medical
             conditions if the dose and regimen have been stable for at least 2 months prior to
             giving informed consent.

          -  Patient demonstrates compliance with the electronic headache diary during the
             screening period by entry of headache data on a minimum of 24 of 28 days and the
             entered data is judged appropriate by the investigator.

        Exclusion Criteria:

        Patients who have previously failed (lack of efficacy) 2 or more of the clusters of the
        medications for treatment of migraine after use for at least 3 months at accepted migraine
        therapeutic doses

        - Hematological, cardiac, renal, endocrine, pulmonary, gastrointestinal, genitourinary,
        neurologic, hepatic, or ocular disease considered clinically significant in the judgment of
        the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takehisa Matsumaru</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saitama Medical University Hospital</name>
      <address>
        <city>Iruma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 2, 2017</study_first_submitted>
  <study_first_submitted_qc>October 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2017</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

